Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 23NIH 5INDUSTRY 4OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma 2Small Cell Lung Carcinoma 1Osteosarcoma 1Neoplasms, Germ Cell and Embryonal 1Hodgkin Disease 1

Interventions

Vinorelbine 3Gemcitabine 3Ifosfamide 2Cyclophosphamide 2zanubrutinib 1treosulfan 1plerixafor 1pegylated granulocyte colony-stimulating factor 1obinutuzumab 1ibritumomab tiuxetan 1fludarabine 1entecavir 1Thiotepa 1Rituximab 1Ice 1Guanosine Diphosphate 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1EPOCH protocol 1Drug Therapy 1Cytarabine 1CVAD protocol 11-(1-glycero)dodeca-1,3,5,7,9-pentaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Lymphoma, Non-Hodgkin × Ifosfamide × Clear all
NCT00280878 2016-01-15

Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma

Bayside Health

Phase 2 Completed
12 enrolled
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

NCT00163761 2016-01-08

Efficacy Study of Outpatient Therapy for Lymphoma

Bayside Health

Phase 2 Completed
90 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡